R. Avery Bennett

Northwell Health — United States

Environmental Science · Physical Sciences

28h-index2.3kcitations140works1.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Turtle Biology and Conservation(17), Bird parasitology and diseases(14), RNA Interference and Gene Delivery(12), Veterinary Equine Medical Research(12), CAR-T cell therapy research(12)

Publications140 total

ASPIRIN ENHANCES ENDOMETRIAL STROMAL CELL DECIDUALIZATION IN VITRO AMONG PATIENTS WITH AND WITHOUT ENDOMETRIOSIS
Fertility and Sterility·2025
Identifying a unique signature of sepsis in patients with pre-existing cirrhosis
Critical Care·2025· 2 citedOpen Access
In vitro elution of amikacin, cefazolin, gentamicin, ampicillin/sulbactam, and meropenem from a commercially available calcium sulfate delivery kit
Frontiers in Veterinary Science·2024· 1 citedOpen Access
Phosgene-induced ARDS: Evaluation of Terbutaline in Large Swine Model
2024
Artificial Intelligence and Machine Learning in Precision Health: An Overview of Methods, Challenges, and Future Directions
Springer optimization and its applications·2024· 3 cited
Lateral ear canal resection and bulla osteotomy with marsupialization to treat otitis media in rabbits: forty‐eight procedures
Veterinary Surgery·2023· 11 citedOpen Access
The Impact of BMI on Mortality Following Primary Graft Dysfunction: A Lung Transplant Outcomes Group Study
2023
Figure S1 from Targeting Treatment-Resistant Breast Cancer Stem Cells with FKBPL and Its Peptide Derivative, AD-01, via the CD44 Pathway
2023Open Access
Figure S4 from Targeting Treatment-Resistant Breast Cancer Stem Cells with FKBPL and Its Peptide Derivative, AD-01, via the CD44 Pathway
2023Open Access
Figure S4 from Targeting Treatment-Resistant Breast Cancer Stem Cells with FKBPL and Its Peptide Derivative, AD-01, via the CD44 Pathway
2023Open Access
Figure S2 from Targeting Treatment-Resistant Breast Cancer Stem Cells with FKBPL and Its Peptide Derivative, AD-01, via the CD44 Pathway
2023Open Access
Figure S7 from Targeting Treatment-Resistant Breast Cancer Stem Cells with FKBPL and Its Peptide Derivative, AD-01, via the CD44 Pathway
2023Open Access
Supplementary Data Legends from Targeting Treatment-Resistant Breast Cancer Stem Cells with FKBPL and Its Peptide Derivative, AD-01, via the CD44 Pathway
2023Open Access
Figure S7 from Targeting Treatment-Resistant Breast Cancer Stem Cells with FKBPL and Its Peptide Derivative, AD-01, via the CD44 Pathway
2023Open Access
Figure S3 from Targeting Treatment-Resistant Breast Cancer Stem Cells with FKBPL and Its Peptide Derivative, AD-01, via the CD44 Pathway
2023Open Access
Table S1 from Targeting Treatment-Resistant Breast Cancer Stem Cells with FKBPL and Its Peptide Derivative, AD-01, via the CD44 Pathway
2023Open Access
Figure S5 from Targeting Treatment-Resistant Breast Cancer Stem Cells with FKBPL and Its Peptide Derivative, AD-01, via the CD44 Pathway
2023Open Access
Figure S2 from Targeting Treatment-Resistant Breast Cancer Stem Cells with FKBPL and Its Peptide Derivative, AD-01, via the CD44 Pathway
2023Open Access
Table S1 from Targeting Treatment-Resistant Breast Cancer Stem Cells with FKBPL and Its Peptide Derivative, AD-01, via the CD44 Pathway
2023Open Access
Figure S6 from Targeting Treatment-Resistant Breast Cancer Stem Cells with FKBPL and Its Peptide Derivative, AD-01, via the CD44 Pathway
2023Open Access
page 1 of 7Next →

Frequent Co-authors

Elliott R. Jacobson(8), Kent A. Vliet(6), Geoffrey W. Pye(6), Daniel R. Brown(4), Pamela E. Ginn(4), Kelly E. Helmick(4), A. Rick Alleman(3), Michael McFadden(3), Guillaume Ragetly(3), Lana McClements(3), Anita Yakkundi(3), Hayley D. McKeen(3), Helen O. McCarthy(3), Tracy Robson(3), Juergen Schumacher(3), Susan M. Newell(3), Tracy L. Clippinger(3), Márcia Furlan Nogueira(3), Trenton R. Schoeb(3), Patricia M. Dennis(2)